GLB1L3 encodes a galactosidase enzyme that cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans, with primary cellular localization to vacuoles. While its specific enzymatic function is well-characterized, clinical relevance remains emerging and incompletely understood. Genome-wide association studies have identified GLB1L3 as associated with prediabetes status change, with robust meta-analysis evidence (p = 3.16×10⁻⁷) across the ARIC and Framingham Heart Study cohorts, with expression enriched in diabetes-relevant tissues 1. Additionally, GLB1L3 has been implicated in spina bifida susceptibility through exome-wide association analysis as part of a complex genetic architecture involving 16 genes 2. The gene was also identified among novel copy number variants associated with tetralogy of Fallot in Han Chinese populations, residing within the 11q25 region 3. In brucellosis pathogenesis, GLB1L3 emerged as a hub gene through machine learning-driven biomarker discovery, potentially relevant to inflammatory responses and immune regulation 4. Despite abundant epididymal expression, GLB1L3 deletion in mice does not impair male fecundity or sperm function 5, indicating redundancy or non-essential roles in reproduction. The gene's broader clinical significance in metabolic, developmental, and infectious disease contexts warrants further investigation.